Physician profile
Amit Ghose
NPI 1639177686
$9,790.01
in general payments reported to CMS, 2019-2025
61 companies · $1,999 in 2025
The $1,999 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,632 · 2020: $874 · 2021: $932 · 2022: $1,149 · 2023: $1,545 · 2024: $1,660 · 2025: $1,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,204.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $907.51 | 2019-2025 | |
| Abbvie INC. | $833.41 | 2021-2025 | |
| Novo Nordisk INC | $732.82 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $720.97 | 2019-2023 | Xarelto |
| Amgen INC. | $575.01 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $502.22 | 2019-2025 | Gardasil 9, Gardasil, Zerbaxa |
| Otsuka America Pharmaceutical, INC. | $491.91 | 2022-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.71 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $330.50 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $325.28 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Gilead Sciences, INC. | $316.79 | 2019-2024 | Veklury, Ambisome |
| Glaxosmithkline, LLC. | $291.89 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $280.90 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $247.46 | 2025 | Fanapt |
| Medtronic, INC. | $206.36 | 2023-2025 | Activos 10 Bone Cement, Interstim |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $169.00 | 2023-2025 | Tymlos |
| Lilly USA, LLC | $162.68 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $162.08 | 2019-2020 | |
| Antares Pharma, INC. | $148.14 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Axsome Therapeutics, INC. | $145.57 | 2024-2025 | Auvelity, Sunosi |
| Boston Scientific Corporation | $137.12 | 2023-2025 | Watchman Flx |
| Nevro Corp. | $103.73 | 2019 | |
| Viiv Healthcare Company | $95.49 | 2024-2025 | Apretude, Rukobia |
| E.R. Squibb & Sons, L.L.C. | $95.22 | 2019-2025 | Eliquis |
| Lundbeck LLC | $92.81 | 2020-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $86.45 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $73.06 | 2021 | |
| Mylan Specialty L.P. | $72.89 | 2020-2024 | Yupelri |
| Abbott Laboratories | $65.06 | 2020-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $64.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $59.30 | 2019-2022 | |
| Sanofi Pasteur INC. | $55.85 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $53.08 | 2021-2023 | |
| Esperion Therapeutics, INC. | $52.57 | 2020 | |
| Dexcom, INC. | $50.80 | 2024-2025 | Dexcom G6 Transmitter |
| Penumbra, INC. | $49.46 | 2022-2023 | Indigo System |
| Amarin Pharma, INC. | $46.44 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $46.33 | 2021-2022 | |
| Seqirus USA INC | $41.99 | 2023-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $39.19 | 2019-2025 | Trintellix |
| Grifols USA, LLC | $36.18 | 2023-2024 | Prolastin-C Liquid |
| Halozyme INC | $33.82 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $33.13 | 2019-2024 | Uptravi, Opsumit |
| Eisai INC. | $32.44 | 2020-2025 | |
| Abiomed | $31.66 | 2023-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $30.01 | 2025 | |
| Grt US Holding, INC. | $29.56 | 2021-2022 | |
| Melinta Therapeutics, LLC | $29.55 | 2023-2024 | Rezzayo, Kimyrsa, Vabomere |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.96 | 2023-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.84 | 2019-2021 | |
| Chiesi USA, INC. | $23.90 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.88 | 2024 | Belbuca |
| Sumitomo Pharma America, INC. | $16.93 | 2023 | Gemtesa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.62 | 2023 | Rexulti |
| Aimmune Therapeutics, INC. | $15.87 | 2025 | Zenpep |
| Insmed, INC. | $15.58 | 2025 | Brinsupri |
| Averitas Pharma INC. | $13.01 | 2023 | Qutenza |
| Xeris Pharmaceuticals, INC. | $12.96 | 2022 | |
| Electromed, INC. | $12.42 | 2022 | |
| Phadia US INC. | $11.81 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Ghose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.